Visual Abstract
The Real-WECAN study assessed in a real-world setting the efectiveness and safety of canagliflozin 100 mg (add-on therapy in SGLT-2i naïve individuals) and canagliflozin 300 mg (switching from canagliflozin 100 mg or other SGLT-2i) in patients with T2DM. The aim of this analysis is to determine baseline predictors of renal function decline over the follow-up. A multiple linear regression analysis estimated the best predictive model of eGFR reduction using the Mallows criterion. 583 patients were included, mean age 60.4 years, A1C 7.76%, BMI 34.7 kg/m2, eGFR 85.6 ml/min, eGFR<60 ml/min 8.6%, albuminuria >30 mg/g 22.8%, median follow-up 13 months. There was a modest mean decrease in eGFR (-1.9 ml/min, p<0.0001) at the end of the follow-up. The best predictive model included age, hypertension, combined hyperlipidemia, heart failure, eGFR and macroalbuminuria (Table). Canagliflozin dose, diuretic therapy or advanced stages of chronic kidney disease were not associated to a higher decrease in eGFR.
In summary, in the Real-WECAN study, patients with older age, combined hyperlipidemia, heart failure, higher baseline eGFR and macroalbuminuria showed greater reductions in eGFR after canagliflozin therapy.
J. J. Gorgojo-martinez: Research Support; Self; AstraZeneca, Novo Nordisk, Speaker’s Bureau; Self; Abbott, AstraZeneca, Lilly Diabetes, Mundipharma International, Novartis Pharmaceuticals Corporation, Novo Nordisk. J. E. M. Wong-cruz: None. M. Brito: Advisory Panel; Self; MSD Corporation, Novo Nordisk, Sanofi, Speaker’s Bureau; Self; Abbott Diabetes, Almirall, S. A., Amgen Inc., AstraZeneca, Eli Lilly and Company, Esteve, MSD Corporation, Mundipharma International, Novo Nordisk, Sanofi-Aventis. T. Antón-bravo: None. A. Galdon-sanzpastor: Speaker’s Bureau; Self; AstraZeneca, Mundipharma International, Novo Nordisk Inc., Sanofi. M. A. Gargallo-fernandez: None.
